These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 15993086)

  • 1. Design, synthesis, and evaluation of novel 2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-ones as NK1 antagonists.
    Seto S; Tanioka A; Ikeda M; Izawa S
    Bioorg Med Chem; 2005 Oct; 13(20):5717-32. PubMed ID: 15993086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-substituted-4-aryl-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,5]oxazocin-5-one as a structurally new NK1 antagonist.
    Seto S; Tanioka A; Ikeda M; Izawa S
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1485-8. PubMed ID: 15713412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of novel 9-substituted-7-aryl-3,4,5,6-tetrahydro-2H-pyrido[4,3-b]- and [2,3-b]-1,5-oxazocin-6-ones as NK(1) antagonists.
    Seto S; Tanioka A; Ikeda M; Izawa S
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1479-84. PubMed ID: 15713411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a Bicyclic Pyrimidine Derivative (KRP-103), a Novel Selective Tachykinin NK1 Receptor Antagonist, on Bladder Function in Guinea Pigs.
    Tanioka A; Deguchi T
    Drug Res (Stuttg); 2017 May; 67(5):302-307. PubMed ID: 28268237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of crucial structural requirements of 2-substituted pyrimido[4,5-b][1,5]oxazocines as NK(1) receptor antagonist by axially chiral derivatives.
    Seto S; Asano J
    Bioorg Med Chem; 2007 Aug; 15(15):5083-9. PubMed ID: 17540575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naphtho[2,1-b][1,5] and [1,2-f][1,4]oxazocines as selective NK1 antagonists.
    Ohnmacht CJ; Albert JS; Bernstein PR; Rumsey WL; Masek BB; Dembofsky BT; Koether GM; Andisik DW; Aharony D
    Bioorg Med Chem; 2004 May; 12(10):2653-69. PubMed ID: 15110847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Process development and large-scale synthesis of NK1 antagonist.
    Araya I; Kanazawa S; Akita H
    Chem Pharm Bull (Tokyo); 2008 Feb; 56(2):176-80. PubMed ID: 18239303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ava[L-Pro9,N-MeLeu10] substance P(7-11) (GR 73632) and Sar9, Met(O2)11 increase distention-induced peristalsis through activation of neurokinin-1 receptors on smooth muscle and interstitial cells of cajal.
    Nieuwmeyer F; Ye J; Huizinga JD
    J Pharmacol Exp Ther; 2006 Apr; 317(1):439-45. PubMed ID: 16330493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists.
    Hipskind PA; Howbert JJ; Bruns RF; Cho SS; Crowell TA; Foreman MM; Gehlert DR; Iyengar S; Johnson KW; Krushinski JH; Li DL; Lobb KL; Mason NR; Muehl BS; Nixon JA; Phebus LA; Regoli D; Simmons RM; Threlkeld PG; Waters DC; Gitter BD
    J Med Chem; 1996 Feb; 39(3):736-48. PubMed ID: 8576917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
    Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
    Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of dibenz[b,f][1,5]oxazocine derivatives for agonist activity at κ-opioid receptor.
    Mitra S; Banerjee TS; Hota SK; Bhattacharya D; Das S; Chattopadhyay P
    Eur J Med Chem; 2011 May; 46(5):1713-20. PubMed ID: 21392859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder.
    Yusup A; Akino H; Miwa Y; Oyama N; Aoki Y; Ito H; Tanase K; Matsuta Y; Nakai M; Yokoyama O
    Eur J Pharmacol; 2007 Dec; 577(1-3):143-9. PubMed ID: 17904547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.
    Di Fabio R; Griffante C; Alvaro G; Pentassuglia G; Pizzi DA; Donati D; Rossi T; Guercio G; Mattioli M; Cimarosti Z; Marchioro C; Provera S; Zonzini L; Montanari D; Melotto S; Gerrard PA; Trist DG; Ratti E; Corsi M
    J Med Chem; 2009 May; 52(10):3238-47. PubMed ID: 19388677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic urea derivatives as potent NK1 selective antagonists. Part II: Effects of fluoro and benzylic methyl substitutions.
    Shue HJ; Chen X; Schwerdt JH; Paliwal S; Blythin DJ; Lin L; Gu D; Wang C; Reichard GA; Wang H; Piwinski JJ; Duffy RA; Lachowicz JE; Coffin VL; Nomeir AA; Morgan CA; Varty GB; Shih NY
    Bioorg Med Chem Lett; 2006 Feb; 16(4):1065-9. PubMed ID: 16290143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axially chiral 1,7-naphthyridine-6-carboxamide derivatives as orally active tachykinin NK(1) receptor antagonists: synthesis, antagonistic activity, and effects on bladder functions.
    Natsugari H; Ikeura Y; Kamo I; Ishimaru T; Ishichi Y; Fujishima A; Tanaka T; Kasahara F; Kawada M; Doi T
    J Med Chem; 1999 Sep; 42(19):3982-93. PubMed ID: 10508446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of 3,5-disubstituted benzamide analogues of DNK333 as dual NK1/NK2 receptor probes.
    Swarna VM; Undem BJ; Korlipara VL
    Bioorg Med Chem Lett; 2007 Feb; 17(4):890-4. PubMed ID: 17169559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological properties of TD-6301, a novel bladder selective muscarinic receptor antagonist.
    McNamara A; Pulido-Rios MT; Sweazey S; Obedencio GP; Thibodeaux H; Renner T; Armstrong SR; Steinfeld T; Hughes AD; Wilson RD; Jasper JR; Mammen M; Hegde SS
    Eur J Pharmacol; 2009 Mar; 605(1-3):145-52. PubMed ID: 19168050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
    Tsuchida H; Takahashi S; Nosaka E; Mukaiyama O; Yamashita M; Morimoto K
    Eur J Pharmacol; 2008 May; 586(1-3):306-12. PubMed ID: 18353309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of a new series of heterocyclic scaffolds for medicinal purposes.
    Hilal HS; Ali-Shtayeh MS; Arafat R; Al-Tel T; Voelter W; Barakat A
    Eur J Med Chem; 2006 Aug; 41(8):1017-24. PubMed ID: 16797790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel short chain 4-substituted indoles as potent alphavbeta3 antagonist using structure-based drug design.
    Raboisson P; Desjarlais RL; Reed R; Lattanze J; Chaikin M; Manthey CL; Tomczuk BE; Marugán JJ
    Eur J Med Chem; 2007 Mar; 42(3):334-43. PubMed ID: 17184884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.